#UNIT 4402 REPORTING | Explore Tumblr Posts and Blogs

albus077 · 8 months

Text

Carbon Fiber Reinforced Plastic Market

Research Nester published a report titled “Carbon Fiber Reinforced Plastic Market: Global Demand Analysis & Opportunity Outlook 2033” which delivers detailed overview of the global carbon fiber reinforced plasticin terms of market segmentation by raw material, type, application, and by region.

Further, for the in-depth analysis, the report encompasses the industry growth indicators, restraints, supply and demand risk, along with detailed discussion on current and future market trends that are associated with the growth of the market.

The global carbon fiber reinforced plastic market is anticipated to grow with a CAGR of ~8% during the forecast period, i.e. 2023-2033. The market is segmented by application into aerospace & defense, wind turbine, automotive, sports equipment, building & construction, and others. Out of these, the automotive segment is attributed to garner the highest market share by 2033, owing to the high sales of the vehicles across the globe. As per Organization of Motor Vehicle Manufacturers, the sales of vehicles rose from 78, 774,320 units in 2020 to 82, 684, 788 in 2021.

The global carbon fiber reinforced plastic market is estimated to garner a notable revenue by 2033. Carbon fiber reinforced plastics are being highly utilized owing to their beneficial characteristics such as high load bearing capacity, light weight, and high fatigue strength. Safety is considered the primary factor in the automotive sector, and thus the advantages of carbon fiber reinforced plastic make it the most preferred option. Also, carbon fiber reinforced plastics are good at absorbing high impact energy as compared to steel, making them ideal for producing luxury cars. Also, carbon fiber reinforced plastics are 30 times lighter than aluminum, making it viable to enhance the performance of vehicles.

Geographically, the global carbon fiber reinforced plastic market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. Out of these, the market in Asia Pacific region is estimate to garner the largest market share by the end of 2033, on the back of increased sales and production of vehicles. International Organization of Motor Vehicles, stated that the total production of vehicles in the region was 46,732,785 units in 2021, a rise from 44,276,549 units in 2020. Similarly, the total sales in the region was 42,663,736 units in 2021, a rise from 40,322,544 in 2020.

The research is global in nature and covers detailed analysis on the market in North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC [Finland, Sweden, Norway, Denmark], Poland, Turkey, Russia, Rest of Europe), Latin America (Brazil, Mexico, Argentina, Rest of Latin America), Asia-Pacific (China, India, Japan, South Korea, Indonesia, Singapore, Malaysia, Australia, New Zealand, Rest of Asia-Pacific), Middle East and Africa (Israel, GCC [Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman], North Africa, South Africa, Rest of Middle East and Africa). In addition, analysis comprising market size, Y-O-Y growth & opportunity analysis, market players’ competitive study, investment opportunities, demand for future outlook etc. has also been covered and displayed in the research report.

Request Report Sample@ https://www.researchnester.com/sample-request-4402

Expand of Aerospace & Defense Industry to Drive the Market Growth

CFRPs are composite materials created by fusing a resin with carbon fiber reinforcement. They are suited for usage in a variety of industrial applications due to their considerable weight savings, enhanced tensile strength, fatigue resistance, impact resistance, and durability. CFRP materials are increasingly being used in place of metals in a variety of automobile applications, largely to minimize fuel consumption. They are utilized in the production of tennis racquets, aerospace and automotive components, protective helmets, wind turbine blades, molding compounds, building and construction plates, and imaging equipment structures. Because carbon is a potent absorbent, these materials can be utilized as chemical or water purifiers.

However, easy availability of other materials along with high costs incurred and long production cycles is expected to operate as key restraints to the growth of the global carbon fiber reinforced plastic market over the forecast period.

This report also provides the existing competitive scenario of some of the key players of the global carbon fiber reinforced plastic market which includes company profiling of SGL CARBON SE, Toray Industries, Inc., Röchling SE & Co. KG, Nikkiso Co., Ltd., Formosa Plastics Corporation, U.S.A., Teijin Limited, Hexcel Corporation, PHC Holdings Corporation, Nikkiso Co., Ltd., Nippon Graphite Fiber Co., Ltd., Solvay Group, and many more. The profiling enfolds key information of the companies which encompasses business overview, products and services, key financials and recent news and developments. On the whole, the report depicts detailed overview of the global carbon fiber reinforced plastic market that will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.

0 notes

roosevelthouseppi · 8 months

Text

New Study Reveals Upsurge in Unionization and Strikes in Higher Education

Media Contacts: Ruth Milkman, 310-871-3055 William Herbert, 518-605-4402 NEW YORK, NY (August 31, 2023)— A new report released by the CUNY School of Labor and Urban Studies, State of the Unions 2023: A Profile of Organized Labor in New York City, New York State, and the United States, is a part of an annual publication series, documents recent trends in unionization patterns. As Figure 1a shows,…

View On WordPress

0 notes

didanawisgi · 3 years

Link

Science’s COVID-19 reporting is supported by the Pulitzer Center.

On its face, it was a major finding: Antimalarial drugs touted by the White House as possible COVID-19 treatments looked to be not just ineffective, but downright deadly. A study published on 22 May in The Lancet used hospital records procured by a little-known data analytics company called Surgisphere to conclude that coronavirus patients taking chloroquine or hydroxychloroquine were more likely to show an irregular heart rhythm—a known side effect thought to be rare—and were more likely to die in the hospital.

Within days, some large randomized trials of the drugs—the type that might prove or disprove the retrospective study’s analysis—screeched to a halt. Solidarity, the World Health Organization’s (WHO’s) megatrial of potential COVID-19 treatments, paused recruitment into its hydroxychloroquine arm, for example. (Update: At a briefing on 3 June WHO announced it would resume that arm of the study.)

But just as quickly, the Lancet results have begun to unravel—and Surgisphere, which provided patient data for two other high-profile COVID-19 papers, has come under withering online scrutiny from researchers and amateur sleuths. They have pointed out many red flags in the Lancet paper, including the astonishing number of patients involved and details about their demographics and prescribed dosing that seem implausible. “It began to stretch and stretch and stretch credulity,” says Nicholas White, a malaria researcher at Mahidol University in Bangkok.

Today, The Lancet issued an Expression of Concern (EOC) saying “important scientific questions have been raised about data” in the paper and noting that “an independent audit of the provenance and validity of the data has been commissioned by the authors not affiliated with Surgisphere and is ongoing, with results expected very shortly.”

Hours earlier, The New England Journal of Medicine (NEJM) issued its own EOC about a second study using Surgisphere data, published on 1 May. The paper reported that taking certain blood pressure drugs including angiotensin-converting enzyme (ACE) inhibitors didn’t appear to increase the risk of death among COVID-19 patients, as some researchers had suggested. (Several studies analyzing other groups of COVID-19 patients support the NEJM results.) “Recently, substantive concerns have been raised about the quality of the information in that database,” an NEJMstatement noted. “We have asked the authors to provide evidence that the data are reliable.”

A third COVID-19 study using Surgisphere data has also drawn fire. In a preprint first posted in early April, Surgisphere founder and CEO Sapan Desai and co-authors conclude that ivermectin, an antiparasitic drug, dramatically reduced mortality in COVID-19 patients. In Latin America, where ivermectin is widely available, that study has led government officials to authorize the drug—although with precautions—creating a surge in demand in several countries.

Chicago-based Surgisphere has not publicly released the data underlying the studies, but today Desai told Science through a spokesperson that he was “arranging a nondisclosure agreement that will provide the authors of the NEJM paper with the data access requested by NEJM.”

Meanwhile, the questions swirling around the Lancet paper have left leaders of the halted chloroquine trials weighing whether to restart. “The problem is, we are left with all the damage that has been done,” says White, a co-investigator on a trial of hydroxychloroquine for COVID-19 prevention that was halted at the request of U.K. regulators last week. Headlines proclaiming deadly effects will make it hard to recruit patients to key studies, he says. “The whole world thinks now that these drugs are poisonous.”

A striking observation

Desai’s co-authors on the Lancet paper were cardiologist Mandeep Mehra of Harvard University’s Brigham and Women’s Hospital (BWH), cardiologist Frank Ruschitzka of the University Hospital Zürich, and cardiac surgeon Amit Patel, who listed affiliations with the University of Utah and HCA Research Institute in Nashville, Tennessee. Their study described an analysis of Surgisphere-provided electronic health record data from patients already treated for COVID-19 at 671 hospitals on six continents.

According to the paper, the analysis included nearly 15,000 patients prescribed chloroquine or hydroxychloroquine, alone or in combination with a class of antibiotics that has been suggested to boost its effects. A control group consisted of more than 81,000 patients who hadn’t gotten the experimental drugs. After controlling for potentially confounding factors such as age, race, pre-existing disease, and COVID-19 severity, the researchers found that the risk of dying in the hospital was 9.3% for the control group versus 23.8% for those getting hydroxychloroquine alongside an antibiotic—apparently the riskiest of the treatment combinations. The results echoed a preprint published last month, based on a much smaller group of patients in U.S. Veterans Health Administration medical centers, which suggested an increased risk of death for patients who were prescribed hydroxychloroquine alone (though not in combination with an antibiotic).

In 25 May media briefing, WHO Director-General Tedros Adhanom Ghebreyesus cited the Lancetresults in announcing a “temporary pause” in Solidarity’s hydroxychloroquine arm. Regulators in France and the United Kingdom also instructed investigators, including White’s team, to halt enrollment in trials of the malaria drug. And Sanofi, which manufactures the branded hydroxychloroquine drug Plaquenil, said it would temporarily stop recruiting patients to its two clinical trials of the drug.

The Lancet authors acknowledged their results needed confirmation from more rigorous randomized trials, but in an interview with TRT World, a Turkish channel for international news, Desai expressed confidence. “The real question is: With data like this, do we even need a randomized controlled trial?” he said.

Other researchers immediately took issue with the analysis. The study doesn’t properly control for the likelihood that patients getting the experimental drugs were sicker than the controls, says Matthew Semler, a critical care physician at Vanderbilt University. “If you have a physician sitting with two patients who have coronavirus, and the physician chooses to give one of them hydroxychloroquine, they’re doing it for a reason,” he says. The patient may be relying on high levels of supplemental oxygen, for example, or getting worse over time. But those kinds of details aren’t available about the patients in the Lancet study, he notes.

Other researchers were befuddled by the data themselves. Though 66% of the patients were reportedly treated in North America, the reported doses tended to be higher than the guidelines set by the U.S. Food and Drug Administration, White notes. The authors claim to have included 4402 patients in Africa, 561 of whom died, but it seems unlikely that African hospitals would have detailed electronic health records for so many patients, White says.

The study also reported more deaths in Australian hospitals than the country’s official COVID-19 death statistics, The Guardian reported. On 29 May, The Lancet issued a correction updating a supplemental table and saying that a hospital assigned to the study’s “Australasia” group should have been assigned to Asia. “There have been no changes to the findings of the paper,” the correction notice said.

Deepening skepticism

The brief response left some researchers frustrated. “This was very, very annoying, that The Lancetwere just going to let them write this absurd reply … without addressing any of the other concerns,” says James Watson, a statistician at Mahidol who on 28 May published an open letter to the journal and the study’s co-authors, signed by more than 200 clinicians and researchers, that calls for the release of Surgisphere’s hospital-level data, an independent validation of the results, and publication of the peer review comments that led to the Lancet publication.

Today, many of the same researchers published an open letter to NEJM and the authors of the ACE inhibitor study, citing similar problems in that journal’s paper. The letter notes a discrepancy between the small number of hospitals in each country that are reported to have shared patient data with Surgisphere and the high proportion of those countries’ confirmed COVID-19 cases reported in the study. It also notes inconsistencies in the reported increases in the risk of COVID-19 death with increasing age of participants.

Mehra and Patel declined to speak to reporters about the various papers, referring inquiries to BWH, which released a statement on Mehra’s behalf this evening saying “independent of Surgisphere, the remaining co-authors of the recent studies published in The Lancet and The New England Journal of Medicine have initiated independent reviews of the data used in both papers after learning of the concerns that have been raised about the reliability of the database.” (Ruschitzka, who is on the Lancet paper, has not yet responded to Science’s requests for comment.)

Oddities also appear in the ivermectin study, says Carlos Chaccour of the Institute for Global Health in Barcelona, who knows the drug well because he’s studying its potential role in mosquito control. There’s evidence that ivermectin has antiviral properties, and a study from an Australian team published in Antiviral Research on 3 April showed that it inhibits SARS-CoV-2 in a test tube. A 6 April preprint co-authored by Patel, Desai, and Mehra, along with David Grainger of the University of Utah, used Surgisphere data reportedly collected at 169 hospitals around the world between 1 January and 1 March. It included three patients in Africa who received ivermectin—despite the fact that only two COVID-19 cases had been reported in all of Africa by 1 March, Chaccour and two colleagues note in a recent blog post.

Chaccour says after he inquired about the discrepancy, the authors posted a second, longer version of the manuscript on 19 April, containing data collected between 1 January and 31 March. (The first version was removed but Chaccour has archived it on his institute’s website.) The new manuscript contained data on 704 COVID-19 patients treated with ivermectin and 704 controls in 169 hospitals on three continents. It reported that ivermectin reduced the need for mechanical ventilation by 65% and slashed the death rate by 83%.

But the revision had other problems, Chaccour and his colleagues wrote in their blog post. For example, the data shown in a figure were wildly different from those reported in the text. (Sciencealso attempted to reach Grainger, but received no reply to an email and call.)

The ivermectin study has had a significant impact in Latin America, where the drug is well known and often sold over the counter to treat scabies, Chaccour says. The Peruvian Health Ministry modified its COVID-19 treatment protocol to include ivermectin (as well as hydroxychloroquine) for mild and severe cases of COVID-19. Demand for the drug in Peru has surged, and in the San Martín de Porres district, police confiscated 20,000 bottles of veterinary ivermectin intended to be sold for human treatments. In Trinidad, Bolivia, the city government aimed to hand out more than 350,000 free doses of ivermectin after the country’s Ministry of Health authorized its use against COVID-19. Physicians in the Dominican Republic, Peru, and Chile, citing the test tube study and the Surgisphere preprint, say they performed informal trials of ivermectin with COVID-19 patients and saw good outcomes.

(In a guest editorial in The American Journal of Hygiene and Tropical Medicine, Chaccour and three colleagues cautioned against the risks of using ivermectin without solid evidence and urged rigorous clinical trials. Eighteen such studies are ongoing, according to the website ClinicalTrials.gov, including one led by Chaccour in Pamplona, Spain.)

Surgisphere’s sparse online presence—the website doesn’t list any of its partner hospitals by name or identify its scientific advisory board, for example—have prompted intense skepticism. Physician and entrepreneur James Todaro of the investment fund Blocktown Capital wondered in a blog postwhy Surgisphere’s enormous database doesn’t appear to have been used in peer-reviewed research studies until May. Another post, from data scientist Peter Ellis of the management consulting firm Nous Group, questioned how LinkedIn could list only five Surgisphere employees—all but Desai apparently lacking a scientific or medical background—if the company really provides software to hundreds of hospitals to coordinate the collection of sensitive data from electronic health records. (This morning, the number of employees on LinkedIn had dropped to three.) And Chaccour wonders how such a tiny company was able to reach data-sharing agreements with hundreds of hospitals around the world that use many different languages and data recording systems, while adhering to the rules of 46 different countries on research ethics and data protection.

Desai’s spokesperson responded to inquiries about the company by saying it has 11 employees and has been developing its database since 2008. Desai, through the spokesperson, also said of the company’s work with patient data: “We use a great deal of artificial intelligence and machine learning to automate this process as much as possible, which is the only way a task like this is even possible.”

What next?

The potential of hydroxychloroquine for treating COVID-19 has become a political flashpoint, and the questions around the Lancet paper have provided new fodder to the drug’s supporters. French microbiologist Didier Raoult, whose own widely criticized studies suggested a benefit from the drug, derided the new study in a video posted today, calling the authors “incompetent.” On social media, some speculated that the paper was part of a conspiracy against hydroxychloroquine.

For scientists running randomized trials of hydroxychloroquine, an urgent question has been how to respond to the paper and the many questions raised about it. Some studies were not halted at all. A hydroxychloroquine trial known as ORCHID, funded by the U.S. National Heart, Lung, and Blood Institute, opted to keep running after its data and safety monitoring board (DSMB) reviewed safety data from already enrolled participants, says Semler, a co-investigator on the study.

WHO’s paused Solidarity trial is awaiting a similar review from its DSMB, says Soumya Swaminathan, the organization’s chief scientist. The pause will allow time for a review of published studies and interim data from Solidarity itself, she says. WHO paused the trial to show investigators and potential study participants that the agency takes safety issues seriously, she says. “We want to reassure people that the WHO didn’t make any kind of value judgment on the use of hydroxychloroquine.”

But some say WHO had a knee-jerk reaction to a questionable study. “This is a drug that has been used for decades. It’s not like we know nothing about its safety,” says Miguel Hernán, a Harvard epidemiologist and co-investigator on an ongoing trial of hydroxychloroquine in Spain and Latin America for COVID-19 prevention in health care workers.

The controversy has been an unfortunate distraction, Hernán adds. “If you do something as inflammatory as this without a solid foundation, you are going to make a lot of people waste time trying to understand what is going on.”

Chaccour says both NEJM and The Lancet should have scrutinized the provenance of Surgisphere’s data more closely before publishing the studies. “Here we are in the middle of a pandemic with hundreds of thousands of deaths, and the two most prestigious medical journals have failed us,” he says.

With reporting by Rodrigo Pérez Ortega, Charlie Piller, and John Travis.

*Correction, 4 June, 10:50 a.m.: An earlier version of this story said one problem with the ivermectin study, according to Carlos Chaccour and his colleagues, was the strikingly low mortality rate, 21%, of COVID-19 patients who needed mechanical ventilation. It stated that a case series in the New York City area found that 88% of COVID-19 patients who needed ventilation died. However, that number was based on a paper in JAMA that was later corrected because the actual mortality for this group was much lower. The sentence has been removed from the story.

#covid-19 #journalism #clinical research #Resources #research #medicine #infectious disease #hydroxychloroquine #politics #ivermectin #family medicine #internal medicine #controversy #debate #infectious diseases

3 notes · View notes

digitalconvo · 3 years

Text

FLAMMABILITY TEST CHAMBER MARKET NEW ERA OF INDUSTRY & FORECAST 2019-2029

Global Flammability Test Chamber Market: Introduction

The flammability test chamber is made of stainless steel including large heat resistant window for the examination of the rate of combustion according to DIN 4402, DIN 53438, and other fire test. It is designed to test the flammability of equipment, appliance, component, and materials. The flammability machine has a wide range of test indicators for end-use such as combustion rate, flammability, flame spread, flame retardant and combustion intensity properties of products which can be tested. The flammability test chamber includes a high precision gas burner as well as an adjustable specimen support. Flammability test chamber also consist of exhaust fan, precise gas control system, flame height indicator and different specimen fixtures and holders.

The flammability test chamber is used for wide range of application such as the flammability testing of plastic materials used in electric devices, the tenacity of comparative burn rates of cloth such as napped and pile cloths, safety performance of the battery such as lithium ion, material used in the vehicle and many more applications

Get Brochure of the Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=6510

Global Flammability Test Chamber Market: Segmentation

Globally, the flammability test chamber market can be segmented on the basis of product type, and end-use industry

Based on the Product Type, the global flammability test chamber market can be segmented into,

Horizontal Flammability Test Chamber

Vertical Flammability Test Chamber

Based on the End-use Industry, the global flammability test chamber market can be segmented into,

Automotive Industry

Textile Industry

Electronics Industry

Building and Construction Industry

Aerospace Industry

Oil and Gas Industry

Pharmaceutical Industry

Global Flammability Test Chamber Market: Dynamics

Some of the standards such as American Society for Testing and Materials (ASTM) international standards organization developed and published technical standards for a wide range of products, materials, services and systems, creating lucrative opportunity for the demand of flammability test chamber. Moreover, the market is estimated drive by factors such as increasing government regulation towards the material used in the vehicle which need to have a degree of burn resistance and flammability in textile industry. For instance, in May 2019, major clothing brand American Apparel has recalled over 10,000 children’s “sleep sacks” because clothing items does not meet the U.S. federal flammability standard and the children’s sleep sacks easily catch fire, which can create burn hazard. Moreover, the fabrics must go through the flammability test because the synthetic fabrics does not burn and rather it melts, which can cause serious burns when they contact skin.

COVID-19:

However, COVID-19 affected countries worldwide, resulted into shutdown and negatively impact the global flammability test chamber market. As the market involved in automotive industry, textile industry, electronics industry, building and construction industry, aerospace industry, and oil & gas industry has slow down at rapid rate. Whereas, the COVID-19 stipulated to have some positive impact on the global flammability test chamber market as the market also worked in pharmaceutical industry.

To get Incredible Discounts on this Report, Click Here @https://www.tmrresearch.com/sample/sample?flag=D&rep_id=6510

Global Flammability Test Chamber Market: Regional Outlook

North America is estimated to hold a significant market share in flammability test chamber market. On the Country level, U.S. is expected to dominate the flammability test chamber market as they have implemented strictest mandatory flammability testing procedures, such as 16 CFR 1610, 16 CFR 1615 and 16 CFR 1616, requirements for clothing in the world in flammability test chamber market. Asia Pacific is estimated to contribute lucratively towards the overall flammability test chamber market as the region is witnessing increased automotive sales over the last decade. Europe is estimated to follow by Asia Pacific region as the increase consumer awareness about the importance of quality products is growing in this region. Latin America and Middle East & Africa are expected to witness less share in flammability test chamber market in the coming years as compared to other regions.

Global Flammability Test Chamber Market: Market Participants

Manufacturers of flammability test chamber are focusing on adding new automatic features in the machine such as automatic control system which is an intelligent instrument that displays the time, counting, burning time, residual flame time, residual burning time, etc. and there is no manuscript timing in the flammability test chamber, the test time of system automatically records in the automatic flammability test chamber machine.

Some of the key players involved in the flammability test chamber market include AMETEK ATLAS, Aegis Scientific, Karg Industrietechnik, Wewon Environmental Chambers Co., Ltd., Dongguan Lonroy Equipment Co., Ltd., DNG Technologies Private Limited, Intertek Group plc, VWR International, LLC, Bemco Inc., WTB Binder Labortechnik GmbH, among others.

The research report presents a comprehensive assessment of the flammability test chamber market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to flammability test chamber market segments such as product type, and application.

The report covers exhaustive analysis on:

Flammability Test Chamber Market Segments

Flammability Test Chamber Market Dynamics

Flammability Test Chamber Market Size

Flammability Test Chamber Volume Sales

Flammability Test Chamber Adoption Rate

Flammability Test Chamber Current Trends/Issues/Challenges

Flammability Test Chamber Competition & Companies involved

Flammability Test Chamber Value Chain

The market report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various factors on flammability test chamber market segments and geographies.

Report Highlights:

Detailed overview of parent market

Changing market dynamics in the industry

In-depth market segmentation

Historical, current, and projected flammability test chamber market size in terms of value

Recent industry trends and developments

Competitive landscape

Strategies of key players and products offered

Potential and niche segments, geographical regions exhibiting promising growth

A neutral perspective on flammability test chamber market performance

Must-have information for flammability test chamber market players to sustain and enhance their market footprint

Request For TOC @ https://www.tmrresearch.com/sample/sample?flag=T&rep_id=6510

About TMR Research:

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in today’s supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients’ conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Contact:

TMR Research, 3739 Balboa St # 1097, San Francisco, CA 94121 United States

Tel: +1-415-520-1050

0 notes

yespastpapercomposts-blog · 4 years

Text

AQA GCSE Pastpapers

AQA GCSE Pastpapers, Exam Papers, Question Papers, Mark Schemes, Grade Thresholds & Syllabus

Pastpapers.co.in offers a wide range of free to use past exam papers, notes, pastpapers and other resources such as question practice papers as well as marking schemes of AQA GCSE tests to ensure you are always ready for that next exam of yours! Download AQA Pastpapers for GCSE many such more, which are always up to date!

The Assessment and Qualifications Alliance (AQA) is an awarding body in England, Wales and Northern Ireland. It compiles specifications and holds examinations in various subjects at GCSE, AS and A Level and offers vocational qualifications. AQA is a registered charity and independent of the government. However, its qualifications and exam syllabi are regulated by the Government of the United Kingdom, which is the regulator for the public examinations system in England and Wales.

AQA is one of five awarding bodies which are recognised by schools across the country. AQA is also recognised by the regulators of the public exams systems for England, Wales and Northern Ireland to offer GCSE, AS and A Levels in the United Kingdom. AQA also offers the AQA Baccalaureate, a qualification also intended for students in Year 12 and 13 and which includes the study of three A-Levels, an extended project and extra-curricular enrichment activities. AQA is the largest examination board for GCSEs and GCE A Levels in England.

Art and Design (8201, 8202, 8203, 8204, 8205, 8206)

Art and Design (4200)

Bengali (8638)

Bengali (4635)

Biology (8461)

Biology (4401)

Business Subjects and Economics (4130)

Business (8132)

Citizenship Studies (8100)

Citizenship Studies (4105)

Chinese (Spoken Mandarin) (8673)

Chinese (Mandarin) (4670)

Chemistry (8462)

Chemistry (4402)

Classical Civilisation (4020)

Computer Science (4512)

ICT (4520)

Computer Science (8520)

Dance (8236)

Dance (4230)

Design and Technology Textiles Technology (4570)

Design and Technology Systems and Control Technology (4565)

Design and Technology Short Course (4575)

Design and Technology Resistant Materials (4560)

Design and Technology Product Design (4555)

Design and Technology Graphic Products (4550)

Design and Technology Food Technology (4545)

Design and Technology Electronic Products (4540)

Design and Technology (8552)

Drama (8261)

Drama (4240)

Engineering (8852)

Engineering (4580)

Electronics (4430)

Economics (8136)

Food Preparation and Nutrition (8585)

Expressive Arts (4260)

Environmental Science (4440)

English Literature (8702)

English Language (8700)

English Language (4705)

English (4700)

French (8658)

French (4655)

General Studies (4760)

Geography B (9035)

Geography A (9030)

Geography (8035)

Health and Social Care (4820)

German (4665)

German (8668)

Humanities (4070)

Human Health and Physiology (4415)

Home Economics Child Development (4580)

Home Economics Food and Nutrition (4585)

History (8145)

History B Full and Short Courses (9145)

Law (4160)

Italian (4630)

Italian (8633)

Leisure and Tourism (4840)

Linked Pair Methods in Mathematics (9365)

Linked Pair Applications of Mathematics (9370)

Media Studies (4810)

Mathematics Linear B (4365)

Mathematics (8300)

Music (4270)

Music (8271)

Modern Hebrew (4675)

Modern Hebrew (8678)

Physical Education (8582)

Physical Education (4890)

Performing Arts (4260)

Performing Arts (4880)

Panjabi (4680)

Panjabi (8683)

Psychology (8182)

Psychology (4180)

Polish (8688)

Polish (4685)

Physics (4403)

Physics (8463)

Religious Studies Short Course (8061)

Religious Studies B Full and Short Courses (4055)

Religious Studies B (8063)

Religious Studies A Full and Short Course (4050)

Religious Studies A (8062)

Spanish (8698)

Sociology (4190)

Spanish (4695)

Sociology (8192)

Statistics (8382)

Statistics (4310)

Urdu (4645)

Urdu (8648)

Search Keywords: AQA GCSE Pastpapers, AQA GCSE Examiner Reports, AQA GCSE question papers, AQA GCSE DipIFR pastpapers, AQA GCSE DipIFR question paper, AQA GCSE DipIFR examiner report. AQA GCSE pastpapers, AQA GCSE question papers, AQA GCSE notes, AQA GCSE examiner reports

0 notes

footymanccave · 5 years

Text

POLL: Who gets the better deal in a Pogba/Neymar swap - Man Utd or PSG?

POLL: Who gets the better deal in a Pogba/Neymar swap - Man Utd or PSG? #MUFC #PSG

Manchester United are toying with the idea of a swap deal of Pogba for Neymar.

Reports suggest that Paris Saint-Germain has approached Man Utd with a swap deal, Neymar for Pogba.

We have seen Ed Woodward bring big names to Manchester United since the departure of Sir Alex Ferguson, such as Falcao, Ibrahimovic, Paul Pogba, Di Maria, Schweinsteiger and most recently Alexis Sanchez.

With…

View On WordPress

0 notes

brisquad-unit-4402 · 11 months

Note

IM LOSING IT OVER YOUR RECENT IKE FIC. LIKE OH MY GOD. its so sweet and heartwrenching i felt just as nervous and anxious as reader the entire time, and when ike reciprocated my heart MELTED AHHH his freckles!!! how kind and beautiful he is, and his confusion turning into acceptance and his SQUEALSSS AAAA. i cant take it this is my fav ike and probably luxiem fic of all time. all of your hard work paid off so well, it was so well structured and emotional and everyone felt so real!! like they arent characters, theyre actual people!!

ahh, now i wish i knew ike's perspective during those stream moments and his reaction to pen and paper ship content HAHA. i imagine he swiftly bookmarks it on his private account but he keeps blushing and his hands shake whenever he sees any fanart WAAAH. maybe one time he sees pen and paper kissing and he cant properly look at the notifications from reader's chat without FLUSHING RED i love them so bad

i love whenever i'm reading a fanfic and it's so sweetly emotional that you feel your own emotions kicking in. so whenever i hear my work has that effect on someone else it's one of the nicest feelings in the world and WHAT DO YOU MEAN FAVORITE IKE AND/OR LUXIEM FIC EVER. that's super high praise thank youuuuu sobsobsob

i mean this is the kindest most /posi way possible but "they aren't charcters, they're actual people" is the scariest compliment i've ever heard. like on one hand i'm genuinely happy! i worked really hard on keeping multifaceted personalities in mind even for the minor characters! but also Oh No. I'm Writing Vtubers. We Need To Play This So Carefully And So Conscious Of The Creator/Audience Boundary Or My Ass Is GONE

real talk one of my most favorite ike things is when he squeals at something cute or because he's embarrassed ahhhh. and his speaking voice gets so high pitched and soft when he's flustered too like?? it's probably my favorite charm point of his

the ogs remember the poll i ran like a month ago about if ike should have freckles or not. shoutout to the landslide victory, if i remember correctly 97% of voters wanted ike with freckles! so glad that worked out, it works so well with the star theme and the difference between an online friendship meeting irl, and how reader loves them because it's a reminder that they have so much to learn about ike and are ready/willing, and also, freckles are just plain adorable. ike is just plain adorable. put them together and if i were richer and thirstier i'd be commissioning an artist

─── ･｡ﾟ☆: *.☽ .* :☆ﾟ. ───

real talk tho i feel like ike goes from 1 to 100 whenever he catches himself simping over reader before the off-collab. either he's really good at acting composed, being normal, just interacting with his best friend like best friends do... or he's a stuttering, blushy mess that wavers like jell-o.

ike's the type of guy to sleepily check twitter before going to bed and whenever he sees pen and paper on his fyp it's like he snaps awake. maybe even squeaks or goes "a!" if it's especially.... you know. sometimes he can't even comprehend that people want him and reader to. well. his mouth goes dry.

and then he feels so dirty and embarrassed just because it's there, but... he's still looking at it. is it bad he's still looking at it? it definitely is but it's captivating, in a way. somehow. the artists are so talented, and somehow they nail your body language to a t, and the way your hair swoops above your eyes, and draw you with the cutest little expressions, and—

ah, who is he kidding.

in moments of weakness it triggers something in him to bury his face a little deeper in his blankets, pretend the screen's light would cool the heat pooling over his cheeks, and search the hashtag himself.

not even three pieces of fanart later, he has to throw his phone face-down on the mattress, cover his blush with a pillow, and now he's definitely squealing. it's healing and it makes him ill. it's... pretty. you're pretty. and he's pretty dumb for letting a silly crush distort itself like this.

the worst part is that some of these line up a little too well with daydreams he wanted to lock away until the end of time. he likes when he takes the lead. the stunned, puppyish expression so rare it only shows up on your face during the biggest plot twists during a stream, but coated in a darkened blush as he pecks them on the cheek, elegant and composed. calm.

ohhhh, this can't be good for his heart. especially when ike himself is so red-faced just thinking of it. calm, his foot.

still with the pillow over his flush, ike feels around for his phone and sets it on his nightstand. he chides himself. that's enough internet for the day, eveland! now quit acting like a shoujo high schooler in love and go to bed already, it's not going to happen!

he sets his face into a determined frown as he lifts the pillow and sets it aside. with any luck, he'd go the rest of the night without thinking of reader and his feelings for them.

the frown eases as he nestles into his blankets and tucks himself in. soft sheets and warm comfort greet him as he shuts his eyes, and he enters the fluffy haze of sleep as he slips into dreamland...

...is what he'd like to say, but not even ten seconds later his eyes snap open and jerks upright in bed. wait, i'm acting like i'm in love?!

he sits with the thought seeping through his brain like a corrosive acid, filing through every little moment he daydreamed about you, and when those don't paint him a picture he likes, he tries to recall the moments he shared with you instead. those are even fonder, and even worse.

he slaps his hands over his face and sighs, and when it sounds lovesick he sighs even more.

✧. ┊ ⁭masterpost ✧. ┊ ⁭kofi

#4402 answers #4402 writes #unit 4402 reporting #ike eveland x reader #ike eveland #luxiem #luxiem x reader #nijisanji en #whoops didn't even mean to write that #i should make a brainrot tag #update: i did 😎#4402 brainrot #pliskinverse

101 notes · View notes

predictoreports · 5 years

Link

The global market size of D-MALIC ACID is $XX million in 2018 with XX CAGR from 2014 to 2018, and it is expected to reach $XX million by the end of 2024 with a CAGR of XX% from 2019 to 2024. There are 3 key segments covered in this report: geography segment, end use/application segment and competitor segment. For geography segment, regional supply, application-wise and type-wise demand, major players, price is presented from 2013 to 2023. This report covers the following regions: * North America * South America * Asia & Pacific * Europe * MEA (Middle East and Africa) The key countries in each region are taken into consideration as well, such as United States, China, Japan, India, Korea, ASEAN, Germany, France, UK, Italy, Spain, CIS, and Brazil etc. For end use/application segment, this report focuses on the status and outlook for key applications. End users sre also listed. * Application I * Application II * Application III For competitor segment, the report includes global key players of D-MALIC ACID as well as some small players. The information for each competitor includes:

#d-malic acid good for skin #d-malic acid melting point #deficiency

0 notes

brisquad-unit-4402 · 2 months

Text

hello i’ve got some thoughts and updates for this blog.

i’ve been on a bit of burnout for a while, including life outside of writing. naturally the termination has sped up that burnout. i’m exhausted and struggling to be graceful about it, but that’s to be expected. i’m not one to sit on my feelings even though i’ve lacked the energy to write. which really bites because that’s my number-one passion really.

however i’ve taken some time to relax by diverting my attention away from social media and niji streams. i’ve relearned an old hobby and splurged a little too much on a new one, and i kind of can’t believe how much i missed drawing on real paper with a real pen and pencil. and thank god the love and deepspace sponsorship wrapped up before the termination, because that game has me in not just a chokehold but like one of those umbilical cords from astral projection. the silver cord? that

i’ve been watching other vtubers lately as well. i’ve always considered adding holostars en to my list but hesitated because everything else on my blog was niji-related.

consider this confirmation that i will be adding holostars’ tempus hq, vanguard and armis, and first stage productions’ avallum to my list of characters i will write for. i admit i’m not as familiar with armis, but i’ll be paying closer attention in the near future as i branch out from strictly watching niji only.

(might also be adding idol corp’s e-sekai? maybe? i watch them once every few months and i haven’t seen pochi or yuko stream since they debuted 💀 no clue on their gen 2 either)

i’ll be overhauling my masterpost for organization soon. so apologies for the horrors about to come… to be clear i will not delete any of my writing so don’t worry!

i’m unsure how much niji i’ll write in the future. give me some time to think as the situation hopefully cools down. i appreciate your patience.

and who knows maybe i’ll write for non-vtuber fandoms too

i think it’s about time i clean my inbox out soon too. i‘ll answer what asks i can and delete the remaining ones. i’ve had a few requests sitting in my inbox for nearly a year now and i’ve recently realized how stressed i was over them and learned about some boundaries i didn’t know i had beforehand, among other things, so so it’s about time i face them head-on. i apologize if i never got to your request! please don’t take it personally if i don’t answer your request. but above all else thank you for being patient, understanding, and kind enough to send in a request. even though i tend to bite off more than i can chew i always get so happy whenever i see a notif in my inbox and i appreciate your time for a little unit 4402.

even though i’m not watching niji streams atm i’m hesitant to stop writing for them because, like, i keep thinking of this clip of doppio saying he feels like he’s allowed to buy healthy/organic food because of fan support and donations, and among other reasons... it’s very easy to make conclusions on people you only know through a screen and i just can’t bring myself to cut them out so abruptly, even if i’m a fan creator on a site none of them use.

idk when i’ll post next and it feels nice to say that. i usually try to post once every 2 weeks, but considering how i’m trying not to think about niji right now and am instead embracing other parts of my life, i dunno. it’s nice. this blog is a major source of joy for me and it feels like i’m preserving what makes it so special for me instead of turning it into a chore. hopefully with time and rest i’ll have a clearer idea of where to go from here.

that’s pretty much everything on my mind, i think? thank you for bearing with me and my yapping. i hope to return soon and that the next time you see me, my blog will be cleaner, more expansive, and with a fresh mindset. take care of yourselves and don’t get immersed in toxicity. don’t forget to do what you love 💛

#unit 4402 reporting #this post was drafted at 3:30 am so hopefully i covered everything

19 notes · View notes